| DC47711 |
Raptinal
|
Raptinal, a agent that directly activates caspase-3, initiates intrinsic pathway caspase-dependent apoptosis. Raptinal is able to rapidly induce cancer cell death by directly activating the effector caspase-3, bypassing the activation of initiator caspase-8 and caspase-9. |
| DC47710 |
Z-VDVAD-FMK
|
Z-VDVAD-FMK is a special inhibitor of caspase-2. Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis. |
| DC46985 |
Gly-Phe β-naphthylamide
|
Gly-Phe β-naphthylamide (Gly-Phe beta-naphthylamide) is a substrate of cathepsin C that accumulates within the lysosome. Gly-Phe-β-naphthylamide can inhibit the cathepsin-dependent activation of caspase-8. |
| DC45549 |
TC11
|
TC11 is a MCL1 degradator and Caspase-9 and CDK1 activator. TC11 is structurally related to immunomodulatory drugs as phenylphthalimide derivative. TC11 induces apoptotic death caused by degradation of MCL1 during prolonged mitotic arrest. |
| DC44021 |
Z-LE(OMe)TD(OMe)-FMK
|
Z-LE(OMe)TD(OMe)-FMK is a selective caspase-8 inhibitor. Z-LE(OMe)TD(OMe)-FMK can inhibit cell apoptosis. |
| DC29006 |
Pralnacasan
|
Pralnacasan (VX-740) is a potent, selective, non-peptide and orally active interleukin-1β converting enzyme (ICE, caspase 1) inhibitor with a Ki of 1.4 nM. Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment. |
| DC28151 |
PETCM
|
PETCM is an activator of caspase-3 and acts as an cytochrome c (cyto c)-dependent manner. PETCM promotes Apaf-1 oligomerization and induces cell apoptosis in HeLa cells. |
